Comments
Loading...
Guardant Health Analyst Ratings and Price Targets | NASDAQ:GH | Benzinga
Guardant Health Inc has a consensus price target of $50.4 based on the ratings of 27 analysts. The high is $73 issued by Morgan Stanley on February 21, 2023. The low is $32 issued by Jefferies on June 3, 2024. The 3 most-recent analyst ratings were released by Barclays, Mizuho, and Stephens & Co. on April 10, 2025, April 10, 2025, and March 26, 2025, respectively. With an average price target of $55 between Barclays, Mizuho, and Stephens & Co., there's an implied 16.72% upside for Guardant Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Barclays
Mizuho
Stephens & Co.
Morgan Stanley
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Guardant Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | 16.72% | Barclays | Luke Sergott51% | $60 → $55 | Maintains | Overweight | Get Alert |
| 04/10/2025 | Buy Now | 16.72% | Mizuho | Anthony Petrone66% | → $55 | Initiates | → Outperform | Get Alert |
| 03/26/2025 | Buy Now | 16.72% | Stephens & Co. | Mason Carrico39% | $55 → $55 | Reiterates | Overweight → Overweight | Get Alert |
| 03/06/2025 | Buy Now | 10.36% | Morgan Stanley | Shannon O'Callaghan52% | $42 → $52 | Maintains | Overweight | Get Alert |
| 02/26/2025 | Buy Now | 6.11% | Piper Sandler | David Westenberg59% | $34 → $50 | Maintains | Overweight | Get Alert |
| 02/24/2025 | Buy Now | 18.85% | Guggenheim | Subbu Nambi45% | $56 → $56 | Reiterates | Buy → Buy | Get Alert |
| 02/24/2025 | Buy Now | 10.36% | Scotiabank | Sung Ji Nam45% | $47 → $52 | Maintains | Sector Outperform | Get Alert |
| 02/24/2025 | Buy Now | 27.33% | Canaccord Genuity | Kyle Mikson35% | $42 → $60 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | 18.85% | Goldman Sachs | Matthew Sykes65% | $49 → $56 | Maintains | Buy | Get Alert |
| 02/21/2025 | Buy Now | 25.21% | Raymond James | Andrew Cooper54% | $39 → $59 | Reiterates | Outperform → Outperform | Get Alert |
| 02/21/2025 | Buy Now | 16.72% | JP Morgan | Rachel Vatnsdal66% | $50 → $55 | Maintains | Overweight | Get Alert |
| 02/21/2025 | Buy Now | 12.48% | Stifel | Daniel Arias78% | $45 → $53 | Maintains | Buy | Get Alert |
| 01/28/2025 | Buy Now | 3.99% | Goldman Sachs | Matthew Sykes65% | $36 → $49 | Maintains | Buy | Get Alert |
| 01/23/2025 | Buy Now | 27.33% | Barclays | Luke Sergott51% | → $60 | Initiates | → Overweight | Get Alert |
| 01/22/2025 | Buy Now | — | Guggenheim | Subbu Nambi45% | — | Reiterates | Buy → Buy | Get Alert |
| 11/07/2024 | Buy Now | 6.11% | JP Morgan | Julia Qin62% | $48 → $50 | Maintains | Overweight | Get Alert |
| 11/07/2024 | Buy Now | -23.6% | Goldman Sachs | Matthew Sykes65% | $32 → $36 | Maintains | Buy | Get Alert |
| 10/30/2024 | Buy Now | -25.72% | Bernstein | Eve Burstein44% | $40 → $35 | Maintains | Outperform | Get Alert |
| 10/17/2024 | Buy Now | 6.11% | Leerink Partners | — | $60 → $50 | Maintains | Outperform | Get Alert |
| 08/21/2024 | Buy Now | -15.11% | UBS | Dan Leonard56% | $32 → $40 | Maintains | Buy | Get Alert |
| 08/13/2024 | Buy Now | -27.84% | Piper Sandler | David Westenberg59% | $30 → $34 | Maintains | Overweight | Get Alert |
| 08/08/2024 | Buy Now | -4.5% | Citigroup | Patrick Donnelly80% | $40 → $45 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | -10.87% | TD Cowen | Dan Brennan60% | $41 → $42 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | -21.48% | Craig-Hallum | Alex Nowark62% | $28 → $37 | Maintains | Buy | Get Alert |
| 08/08/2024 | Buy Now | 1.87% | JP Morgan | Julia Qin62% | $45 → $48 | Maintains | Overweight | Get Alert |
| 07/30/2024 | Buy Now | 6.11% | BTIG | Mark Massaro70% | $45 → $50 | Maintains | Buy | Get Alert |
| 07/18/2024 | Buy Now | -15.11% | B of A Securities | Michael Ryskin46% | $28 → $40 | Maintains | Buy | Get Alert |
| 07/17/2024 | Buy Now | -32.09% | Goldman Sachs | Matthew Sykes65% | $28 → $32 | Maintains | Buy | Get Alert |
| 06/28/2024 | Buy Now | -23.6% | Guggenheim | Subbu Nambi45% | → $36 | Upgrade | Neutral → Buy | Get Alert |
| 06/04/2024 | Buy Now | -19.35% | Canaccord Genuity | Kyle Mikson35% | $30 → $38 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | -32.09% | Jefferies | Tycho Peterson83% | → $32 | Initiates | → Buy | Get Alert |
| 05/24/2024 | Buy Now | -6.62% | Stephens & Co. | Mason Carrico39% | $44 → $44 | Reiterates | Overweight → Overweight | Get Alert |
| 04/29/2024 | Buy Now | -36.33% | Canaccord Genuity | Kyle Mikson35% | $45 → $30 | Maintains | Buy | Get Alert |
| 04/24/2024 | Buy Now | -40.58% | Craig-Hallum | Alex Nowark62% | → $28 | Assumes | → Buy | Get Alert |
| 04/15/2024 | Buy Now | -40.58% | Goldman Sachs | Matthew Sykes65% | $32 → $28 | Maintains | Buy | Get Alert |
| 04/05/2024 | Buy Now | — | Guggenheim | Subbu Nambi45% | — | Reiterates | → Neutral | Get Alert |
| 02/26/2024 | Buy Now | -36.33% | Piper Sandler | David Westenberg59% | $40 → $30 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | -4.5% | JP Morgan | Julia Qin62% | $60 → $45 | Maintains | Overweight | Get Alert |
| 02/23/2024 | Buy Now | -4.5% | Canaccord Genuity | Kyle Mikson35% | $50 → $45 | Maintains | Buy | Get Alert |
| 01/30/2024 | Buy Now | -21.48% | Goldman Sachs | Matthew Sykes65% | $43 → $37 | Maintains | Buy | Get Alert |
| 01/29/2024 | Buy Now | -21.48% | Goldman Sachs | Matthew Sykes65% | $43 → $37 | Maintains | Buy | Get Alert |
| 12/14/2023 | Buy Now | — | Guggenheim | Subbu Nambi45% | — | Initiates | → Neutral | Get Alert |
| 12/13/2023 | Buy Now | — | Wolfe Research | Doug Schenkel72% | — | Initiates | → Peer Perform | Get Alert |
| 11/13/2023 | Buy Now | -42.7% | Raymond James | Andrew Cooper54% | → $27 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/08/2023 | Buy Now | 6.11% | Morgan Stanley | Shannon O'Callaghan52% | $55 → $50 | Maintains | Overweight | Get Alert |
| 10/23/2023 | Buy Now | -4.5% | Goldman Sachs | Matthew Sykes65% | $52 → $45 | Maintains | Buy | Get Alert |
| 10/20/2023 | Buy Now | -4.5% | Goldman Sachs | Matthew Sykes65% | $52 → $45 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 6.11% | Citigroup | Patrick Donnelly80% | $50 → $50 | Reiterates | Buy → Buy | Get Alert |
| 09/28/2023 | Buy Now | -27.84% | Bernstein | Eve Burstein44% | → $34 | Initiates | → Outperform | Get Alert |
| 09/27/2023 | Buy Now | -15.11% | Piper Sandler | David Westenberg59% | → $40 | Upgrade | Neutral → Overweight | Get Alert |
| 08/08/2023 | Buy Now | -15.11% | Piper Sandler | David Westenberg59% | $30 → $40 | Maintains | Neutral | Get Alert |
| 08/07/2023 | Buy Now | 16.72% | Morgan Stanley | Shannon O'Callaghan52% | $60 → $55 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | 6.11% | Citigroup | Patrick Donnelly80% | $40 → $50 | Maintains | Buy | Get Alert |
| 05/26/2023 | Buy Now | -15.11% | Citigroup | Patrick Donnelly80% | → $40 | Upgrade | Neutral → Buy | Get Alert |
| 05/11/2023 | Buy Now | 27.33% | Morgan Stanley | Shannon O'Callaghan52% | $66 → $60 | Maintains | Overweight | Get Alert |
| 05/10/2023 | Buy Now | 16.72% | Credit Suisse | Dan Leonard56% | $60 → $55 | Maintains | Outperform | Get Alert |
| 05/01/2023 | Buy Now | — | OTR Global | — | — | Downgrade | Mixed → Negative | Get Alert |
| 03/09/2023 | Buy Now | -29.97% | Citigroup | Patrick Donnelly80% | $60 → $33 | Downgrade | Buy → Neutral | Get Alert |
| 03/03/2023 | Buy Now | -25.72% | Piper Sandler | David Westenberg59% | $50 → $35 | Maintains | Neutral | Get Alert |
| 02/27/2023 | Buy Now | 40.07% | Morgan Stanley | Shannon O'Callaghan52% | $73 → $66 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 6.11% | BTIG | Mark Massaro70% | $60 → $50 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 27.33% | Canaccord Genuity | Kyle Mikson35% | $65 → $60 | Maintains | Buy | Get Alert |
| 02/24/2023 | Buy Now | 12.48% | Cowen & Co. | Max Masucci27% | $70 → $53 | Maintains | Outperform | Get Alert |
| 02/24/2023 | Buy Now | 37.95% | JP Morgan | Julia Qin62% | $75 → $65 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 27.33% | Credit Suisse | Dan Leonard56% | $70 → $60 | Maintains | Outperform | Get Alert |
| 02/21/2023 | Buy Now | 54.92% | Morgan Stanley | Tejas Savant50% | $80 → $73 | Maintains | Overweight | Get Alert |
| 02/16/2023 | Buy Now | 33.7% | Stephens & Co. | Mason Carrico39% | → $63 | Reiterates | → Overweight | Get Alert |
| 02/06/2023 | Buy Now | -4.5% | Goldman Sachs | Matthew Sykes65% | $70 → $45 | Maintains | Buy | Get Alert |
| 01/05/2023 | Buy Now | -23.6% | Scotiabank | Sung Ji Nam45% | → $36 | Initiates | → Sector Outperform | Get Alert |
| 11/18/2022 | Buy Now | 80.39% | JP Morgan | Julia Qin62% | $100 → $85 | Maintains | Overweight | Get Alert |
| 11/07/2022 | Buy Now | 91% | Stephens & Co. | Mason Carrico39% | $99 → $90 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 48.56% | Goldman Sachs | Matthew Sykes65% | $80 → $70 | Maintains | Buy | Get Alert |
| 11/04/2022 | Buy Now | 48.56% | Credit Suisse | Dan Leonard56% | $80 → $70 | Maintains | Outperform | Get Alert |
| 11/01/2022 | Buy Now | 6.11% | Piper Sandler | David Westenberg59% | $65 → $50 | Downgrade | Overweight → Neutral | Get Alert |
| 10/19/2022 | Buy Now | 86.76% | Craig-Hallum | Alex Nowark62% | → $88 | Initiates | → Buy | Get Alert |
| 10/06/2022 | Buy Now | 110.1% | Stephens & Co. | Mason Carrico39% | → $99 | Initiates | → Overweight | Get Alert |
| 08/25/2022 | Buy Now | 69.78% | Credit Suisse | Dan Leonard56% | → $80 | Initiates | → Outperform | Get Alert |
| 08/08/2022 | Buy Now | 69.78% | Morgan Stanley | Tejas Savant50% | $85 → $80 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 69.78% | Goldman Sachs | Matthew Sykes65% | $90 → $80 | Maintains | Buy | Get Alert |
| 06/03/2022 | Buy Now | 37.95% | Piper Sandler | David Westenberg59% | → $65 | Initiates | → Overweight | Get Alert |
| 05/09/2022 | Buy Now | 80.39% | Morgan Stanley | Tejas Savant50% | $120 → $85 | Maintains | Overweight | Get Alert |
| 05/06/2022 | Buy Now | 112.22% | Citigroup | Patrick Donnelly80% | $120 → $100 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Guardant Health (GH) stock?
The latest price target for Guardant Health (NASDAQ:GH) was reported by Barclays on April 10, 2025. The analyst firm set a price target for $55.00 expecting GH to rise to within 12 months (a possible 16.80% upside). 32 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Guardant Health (GH)?
The latest analyst rating for Guardant Health (NASDAQ:GH) was provided by Barclays, and Guardant Health maintained their overweight rating.
When was the last upgrade for Guardant Health (GH)?
The last upgrade for Guardant Health Inc happened on June 28, 2024 when Guggenheim raised their price target to $36. Guggenheim previously had a neutral for Guardant Health Inc.
When was the last downgrade for Guardant Health (GH)?
The last downgrade for Guardant Health Inc happened on May 1, 2023 when OTR Global changed their price target from N/A to N/A for Guardant Health Inc.
When is the next analyst rating going to be posted or updated for Guardant Health (GH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Guardant Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Guardant Health was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Guardant Health (GH) correct?
While ratings are subjective and will change, the latest Guardant Health (GH) rating was a maintained with a price target of $60.00 to $55.00. The current price Guardant Health (GH) is trading at is $47.09, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
